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Abstract
Introduction: Hereditary angioedema is the commonest inherited disorder of the complement
system and has been associated with several immune glomerular diseases. A case of nephrotic
syndrome and renal impairment due to idiopathic membranous glomerulonephritis in a patient with
hereditary angioedema has not been described before.
Case presentation: We present the first reported case of the association of membranous
nephropathy and hereditary angioedema in a 43-year-old male Caucasian patient who presented
with acute intestinal angioedema, hypertension, acute pancreatitis, renal impairment and
generalised body swelling due to severe nephrotic syndrome. We present the challenges involved
in the clinical management of the patient.
Conclusion: This patient's presentation with severe nephrotic syndrome, renal impairment and
hypertension required aggressive treatment of the membranous nephropathy given the high risk
for progression to end stage renal failure. The contraindication to angiotensin converting enzyme
inhibitors and angiotensin II receptor blockers in this patient, the lack of published evidence on the
use of alkylating agents and other immunosuppressive agents in patients with hereditary
angioedema and the lack of published data on the management of similar cases presented a clinical
challenge in this patient's management.
Introduction
Hereditary C1 esterase inhibitor deficiency (hereditary
angioedema; HAE) is a rare (incidence 1 in 10,000 to 1 in
150,000) autosomal dominant inherited disease of the
complement system characterised by the absence or dys-
function of the protein C1 esterase inhibitor (C1 INH),
which regulates the complement, fibrinolytic, coagulation
and kinin cascades [1]. It is the commonest inherited dis-
order of the complement system which is characteristi-
cally associated with non-pruritic angioedema, most
commonly affecting the respiratory system, the skin and
the gastrointestinal tract [1]. It has been associated with
other immunoregulatory disorders (Table 1).
The association of HAE with membranous glomerulone-
phritis has not been reported before, as we far as we know.
The management of membranous glomerulonephritis in
a patient with HAE would be challenging as angiotensin
converting enzyme inhibitors (ACEIs) and angiotensin 2
receptor blockers (ARBs) which effectively reduce pro-
teinuria and slow the progression of the renal disease [2]
cause angioedema which precludes their use in patients
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with HAE [3]. Although alkylating agents such as chlo-
rambucil and cyclophosphamide and the immunosup-
pressant cyclosporin are effective in the treatment of
membranous nephropathy [2], their safety in a patient
with HAE is unknown. The effect of renal failure on HAE
and vice versa is also unknown. We report a case of neph-
rotic syndrome and renal failure due to membranous
glomerulonephritis in a patient with HAE.
Case presentation
A 43-year-old Caucasian man was first diagnosed with
hereditary angioedema in 1982 after admission to the
intensive care unit with acute airway obstruction. Investi-
gations were consistent with type 1 HAE, showing low C1
esterase inhibitor activity of 0.06 g/litre (normal range
[NR] 0.2 to 0.65 g/litre), low complement C4 and normal
complement C3. He was discharged on 17alpha-ethinyl
testosterone (Danazol). He had had recurrent tonsillitis
and abdominal pain from the age of 4 years leading to
tonsillectomy and appendicectomy. He did not know his
biological family. He had three further admissions with
abdominal pain in the 1990s followed by full recovery
after treatment with subcutaneous adrenaline and fresh
frozen plasma.
He presented to our hospital in 2001 with acute abdomi-
nal pain and generalised body swelling. Clinical examina-
tion showed pallor, generalised oedema and abdominal
tenderness. His blood pressure was 146/90 mmHg. He
had bilateral pleural effusions which were confirmed by
chest radiography. The rest of the examination was unre-
markable. Urine dipstick was positive for protein, nitrates,
leucocytes and a trace of blood. Urine culture was nega-
tive. Serum creatinine and serum albumin were 148
μmol/litre and 13 g/litre, respectively. 24 hour urine pro-
tein excretion was 6.3 g. Serum amylase was elevated (340
IU/litre [NR 35 to 110 U/l]). Serum lipids were also
raised. Haemoglobin and erythrocyte sedimentation rate
(ESR) were 10 g/dl and 80 mm in the first hour (NR < 20
mm), respectively. The following autoimmune serological
tests were negative: antineutrophil cytoplasmic antibod-
ies, antinuclear antibodies, extractable nuclear antigen
antibodies, other lupus serology, antiglomerular base-
ment membrane antibodies and rheumatoid factor. Hep-
atitis screen (hepatitis B and C), liver function tests, serum
protein electrophoresis, C-reactive protein (CRP) and all
his other blood results were normal.
Ultrasound scan showed normal sized kidneys and
ascites, findings confirmed by computerised tomography
(CT) scan. The CT also confirmed acute pancreatitis and
bowel oedema. A renal biopsy performed 4 days after diu-
retic treatment to reduce the oedema showed stage 3
membranous glomerulonephritis (Figure 1).
In conclusion, the patient thus had mild pancreatitis,
acute intestinal angioedema and nephrotic syndrome and
moderate renal impairment due to membranous glomer-
ulonephritis.
Table 1: Types of HAE and some associated immunoregulatory disorders
Type Characteristics Comments Some immunological conditions associated 
with all types of HAE
1 Low or absent C1 esterase inhibitor activity Autosomal dominant. Constitutes 80–85% 
of cases
Systemic lupus erythematosus, 
mesangiocapillary glomerulonephritis, 
autoimmune thyroiditis, rheumatoid arthritis, 
urticaria, other glomerulonephritides, 
Sjögren's syndrome, coagulopathies
2 Normal or raised activity of a dysfunctional 
C1 esterase inhibitor
Autosomal dominant. Constitutes 15–20% 
of the cases
3 Normal C1 esterase inhibitor level and 
function
X linked dominant newly described in 
women
Stage 3 membranous glomerulonephritis with medium-sized  subepithelial dense deposits and basement membrane reac- tion surrounding most of the deposits (arrows) (transmission  electron microscopy, original magnification ×11,000) Figure 1
Stage 3 membranous glomerulonephritis with 
medium-sized subepithelial dense deposits and base-
ment membrane reaction surrounding most of the 
deposits (arrows) (transmission electron microscopy, 
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He was treated with infusion of C1 INH concentrate,
reducing course of prednisolone, starting at 60 mg daily
slowly tapering to 10 mg daily over 2 weeks, bisoprolol 5
mg once daily as well as furosemide 80 mg daily reducing
to 40 mg daily. His abdominal pain resolved within 24
hours and serum amylase normalised after 3 days. He was
discharged 7 days later with serum creatinine of 168
μmol/litre and on losartan potassium which he tolerated.
Proteinuria improved to 2 g per day within 2 weeks of dis-
charge. He had no further attacks of angioedema for 4
weeks.
He was readmitted 4 weeks later with worsening neph-
rotic syndrome and abdominal pain and a rise of serum
creatinine to 415 μmol/litre. Serum albumin was 10 g/
litre while proteinuria was 10 g/day. The losartan was
stopped. He was given an infusion of C1 INH concentrate
and increased doses of prednisolone and furosemide.
Cyclosporine was added. He was discharged 10 days later
with serum creatinine and proteinuria of 293 μmol/litre
and 2 g/day, respectively.
He remained stable on daily prednisolone 5 mg, furosem-
ide 40 mg, bisoprolol 10 mg and cyclosporine 100 mg
twice daily. At follow-up in the low clearance clinic 4
weeks later, proteinuria had improved to less than 1 g per
day. Serum creatinine was 250 μmol/litre. He remained
off the danazol because of the renal impairment.
Discussion
The association of HAE with immunoregulatory disorders
is well documented (Table 1). The commonest reported
glomerular diseases associated with HAE are lupus
nephritis and mesangiocapillary glomerulonephritis.
Brickman et al. [4] evaluated 157 patients manifesting fea-
tures of autoimmunity. Nineteen patients had clinical
immunoregulatory disorders of which five had glomeru-
lonephritis, the majority of which were mesangiocapillary
glomerulonephritis. Pan et al. [5] reported long-term fol-
low-up of four cases of non-SLE glomerulonephritis, none
of whom developed renal failure after 8 to 25 years of fol-
low-up. Three members of the same family with HAE
associated with IgA nephropathy have also been reported
[6]. To our knowledge, the association of HAE and mem-
branous nephropathy has not been previously reported.
Our patient had had HAE for about 20 years before he pre-
sented with nephrotic syndrome. The HAE classically
manifested in childhood and led to tonsillectomy and
appendicectomy before the diagnosis, which is typical
since with no suggestive family history, the condition can
be misdiagnosed leading to patients having unnecessary
surgery [1]. His presentation with recurrent abdominal
pain and respiratory problems, due to intestinal and
upper airway angioedema, respectively, is typical. Acute
pancreatitis is a recognised complication of the condition
[1].
This case illustrates some of the challenges which may be
involved in managing renal impairment and nephrotic
syndrome due to membranous nephropathy in a patient
with HAE. There are not much data on the effect of renal
failure on HAE and, since angioedema causes fluid reten-
tion, this may complicate the management of fluid over-
load states in these patients. It may be difficult to
distinguish between fluid overload and attacks of
angioedema in patients with HAE and renal failure or
nephrotic syndrome [7]. Ohsawa et al. described a case
with end stage renal disease due to membranoprolifera-
tive glomerulonephritis (MPGN) who had difficult wors-
ening fluid retention. This case illustrates the difficulties
in controlling fluid overload as the attacks of angioedema
worsened the fluid retention due to the end stage renal
disease and nephrotic syndrome as in our patient [8].
Our patient had no evidence of SLE or any other immuno-
logical condition. His presentation with membranous
nephropathy causing severe nephrotic syndrome, hyper-
tension and renal impairment indicated a high risk for
progression to end stage renal disease [2]. He would,
therefore, require aggressive treatment. There is clear evi-
dence that ACEIs and/or ARBs effectively reduce proteinu-
ria and delay the progression to end stage renal disease in
membranous nephropathy [2]. However, by interfering
with the contact (kallikrein-kinin) system, ACEIs cause
angioedema and are thus contraindicated in patients with
any history of angioedema [3].
When ARBs were first used in clinical practice, they were
thought to provide an alternative for use in people with
ACEI induced cough and angioedema since they do not
directly interfere with the contact (kallikrein-kinin) sys-
tem. At the time this patient presented, there had been
sporadic case reports of suspected ARB induced
angioedema leading to advice for their use with caution in
patients with a previous history of angioedema. Our
assumption at that time was that losartan would be worth
trying in this patient. Though the patient may have
responded to the losartan given the initial improvement
in proteinuria and renal function, he developed acute
intestinal angioedema which improved on stopping the
losartan and giving him C1 INH concentrate infusion.
There have since been many more reported cases of
angioedema associated with ARBs [9], hence their con-
traindication in people with HAE.
Conclusion
Given the high risk for progression to end stage renal fail-
ure in this patient, the treatment of the membranous
nephropathy would require aggressive control of hisPublish with BioMed Central    and   every 
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blood pressure using antihypertensive drugs other than
the contraindicated ACEIs and ARBs. He would also
require alkylating agents such as chlorambucil and cyclo-
phosphamide or the immunosuppressant cyclosporine
[2] for the management of the membranous nephropa-
thy.
The emergency treatment of HAE includes purified C1
INH concentrate infusion or fresh frozen plasma (con-
tains C1 esterase inhibitor) and/or subcutaneous adrena-
line. Corticosteroids and antihistamines are ineffective.
For long-term prophylaxis, attenuated androgens such as
17alpha-ethinyl testosterone (Danazol) and stanozolol
potent androgens such as oxandrolone and antifibrino-
lytic agents such as tranexamic acid and epsilon aminoc-
aproic acid are effective [10] but their safety in patients
with advanced renal disease is unclear.
Our patient required an increasing dosage of 17alpha-
ethinyl testosterone (Danazol) as the frequency of the
attacks of angioedema increased. However, with the
development of advanced renal disease; he required more
careful monitoring of the prophylactic treatment. He tol-
erated the cyclosporine [11], which we believe, has led to
the improvement in the proteinuria and renal function.
The prognosis of HAE is generally good with treatment
[1]. However, the membranous nephropathy causing
renal impairment has worsened the overall prognosis of
this patient who will most likely require renal replace-
ment therapy in the future. The effect of dialysis and or
renal transplantation on HAE will need to be carefully
assessed. Currently, there are few data in the literature to
inform the best management of this patient.
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